Nagata is to Phosphatidylserine as Dmitry Gabrilovich is to MDSC's...and WHO knows, maybe many feared that Peregrine interfearedon many other Big Pharmas legacy.
The legacy all started back with the late Dr. Phil Thorpe and will continue ...
----------------------
ASH Annual Meeting
2015 Scientific Program
The 2015 Scientific Committee Sessions will be held Saturday, December 5, and Sunday, December 6. Each session will be offered twice. A question-and-answer period will occur at the end of each individual speaker presentation. Invited abstracts of these sessions will be published in the Program Book and on the flash drive containing the annual meeting abstracts. In addition, this information will be available online in early November.
New this year: All Scientific Program sessions will be recorded and made available through ASH On Demand after the meeting. Scientific Program Co-Chairs
Akiko Shimamura, MD, PhD Boston Children's Hospital Boston, MA
Andrew W. Roberts, MBBS, PhD Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital Melbourne, Australia
... ... ...
Scientific Committee on Platelets
Mechanism of Phosphatidylserine Exposure
Sessions Offered Twice:
Saturday, December 5, 2015 9:30 a.m. - 11: 00 a.m. Orange County Convention Center, W312
Sunday, December 6, 2015 7:30 a.m. - 9:00 a.m. Orange County Convention Center, W340
Phospholipids are asymmetrically distributed between the outer and inner leaflets of the plasma membrane. The disruption of such asymmetrical distribution in various processes is epitomized by the exposure of phosphatidylserine (PS), the predominant anionic lipid, on the surface of activated platelets for facilitating coagulation or the surface of apoptotic cells for inducing phagocytosis. This session will describe recent exciting advances in the identification and characterization of novel families of phospholipid scramblases and flippases that mediate PS exposure.
Dr. Shigekazu Nagata will describe the identification of two families of membrane proteins (TMEM16 and XKR families) that promote phospholipid scrambling, and discuss the role of ATP11C, a member of the P4-type ATPases, as a major flippase in the plasma membrane.
Dr. Gary Gilbert will describe a strain-dependent lethality in TMEM16F-deficient mice, as well as the graded deficiency in PS exposure in the surviving mice.
Dr. Johan Heemskerk will discuss how platelets regulate and support thrombin generation, fibrin formation and clot contraction. He will also discuss the complex platelet phenotype presented in Scott syndrome patients and mice deficient in TMEM16 proteins.
Chair:
Renhao Li, PhD Emory University School of Medicine Atlanta, GA Speakers:
Shigekazu Nagata, PhD Osaka University Suita, Japan Flippases and Scramblases at Plasma Membranes that Regulate Phosphatidylserine Exposure
Gary E. Gilbert, MD VA Boston Healthcare System, Harvard Medical School Boston, MA Platelet Phosphatidylserine Exposure, Survival and Blood Coagulation in Mice Lacking TMEM16F
Johan Heemskerk, PhD Maastricht University Maastricht, Netherlands Regulation of Platelet Procoagulant Activity
In the previous post, Nagata went to Canada in 2013 and Brazil in 2014 (Keystone Symposia events..), talking exposure of Phosphatidylserine. Now, this Japanese based lab, is "ALL" about targeting phosphatidylserine. Shigekazu is the expert of "Interferon", just as Peregrine KOL Dmitry Gabrilovich is the expert of MDSC's.
I believe that Nagata knows very well that targeting flipped-PS, is far superior than interferon, or better yet, replace all combinations from Interferon to a PS Targeting based drug, such as Bavituximab.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
AI
